BIOPHARMACEUTICAL CMO AND CRO MARKET ANALYSIS

Regional Analysis

Global Biopharmaceutical CMO and CRO Market: Regional Insights

Based on geography, the global biopharmaceutical CMO and CRO market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period owing to the increasing incidence of chronic diseases, increasing demand for generics and biologics, rise in demand for biosimilars, and rising investments in the biopharmaceutical industry. For instance, in September 2022, Pfizer announced multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs. The partnership will support the development of additional disease models and the creation of the high-resolution models, spanning across a number of therapeutic areas.

Europe and Asia Pacific are also expected to witness robust growth in the global biopharmaceutical CMO and CRO market due to the rise in burden of chronic disease, increasing demand for generics, biologics, and biosimilars, increasing drug discovery and drug development, and rapid growth of the biopharmaceutical industry. For instance, Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the German city's town hall announcing the foundation of European ScreeningPort GmbH, in April 2023, (European Centre for Modern Drug Discovery), a company that will run a state-of-the-art drug discovery service centre.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa